ZEB2 and hepatocellular carcinoma: In combined analysis of cytoplasmic ZEB2 expression in HCCs and PLTs, the group with normal expression of ZEB2 in both HCC and PLT had the worst survival (mean survival time, 37.8 months), the group with normal expression of ZEB2 in either HCC or PLT showed moderate survival (mean survival time, 47.9 months), and the group with overexpression of ZEB2 in both HCC and PLT had the best survival (mean survival time, 59.5 months; P = 0.002; Figure 4C).